Literature DB >> 15063342

Simplified method for determination of rosiglitazone in human plasma.

Matthew W Hruska1, Reginald F Frye.   

Abstract

Rosiglitazone is a thiazolidinedione antihyperglycemic drug used in the treatment of type 2 diabetes mellitus. Rosiglitazone is extensively metabolized by cytochrome P450 2C8 and so may have some utility as an in vivo probe for this enzyme. A liquid chromatographic method using sensitive fluorescence detection and simplified sample processing involving protein precipitation with acetonitrile was developed. The isocratic mobile phase consisted of 10 mM sodium acetate-acetonitrile (pH 5; 60:40, v/v) and was delivered at a flow rate of 1 ml/min to an Alltima phenyl column (250 mm x 4.6 mm, 5 microm). Detection was by fluorescence at (EX/EM) 247/367 for rosiglitazone and 235/310 for the internal standard betaxolol. Intra- and inter-day precision ranged from 3.1 to 8.5% and 2.3 to 5.7%, respectively. No endogenous interference was observed with either rosiglitazone or the internal standard. The assay is simple, economical, precise, and is directly applicable to human pharmacokinetic studies involving single dose rosiglitazone administration.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15063342     DOI: 10.1016/j.jchromb.2004.01.010

Source DB:  PubMed          Journal:  J Chromatogr B Analyt Technol Biomed Life Sci        ISSN: 1570-0232            Impact factor:   3.205


  5 in total

1.  The effect of trimethoprim on CYP2C8 mediated rosiglitazone metabolism in human liver microsomes and healthy subjects.

Authors:  M W Hruska; J A Amico; T Y Langaee; R E Ferrell; S M Fitzgerald; R F Frye
Journal:  Br J Clin Pharmacol       Date:  2005-01       Impact factor: 4.335

2.  Development and validation of a repharsed phase- HPLC method for simultaneous determination of rosiglitazone and glimepiride in combined dosage forms and human plasma.

Authors:  Nahed M El-Enany; Amina A Abdelal; Fathalla F Belal; Yoshinori I Itoh; Mitsuhiro N Nakamura
Journal:  Chem Cent J       Date:  2012-01-26       Impact factor: 4.215

3.  The antidiabetic drug rosiglitazone blocks Kv1.5 potassium channels in an open state.

Authors:  Hyang Mi Lee; Sang June Hahn; Bok Hee Choi
Journal:  Korean J Physiol Pharmacol       Date:  2022-03-01       Impact factor: 2.016

4.  Spectrophotometric Determination of Poorly Water Soluble Drug Rosiglitazone Using Hydrotropic Solubilization technique.

Authors:  A P Sherje; K J Desai
Journal:  Indian J Pharm Sci       Date:  2011-09       Impact factor: 0.975

5.  Influence of SLCO1B1 and CYP2C8 gene polymorphisms on rosiglitazone pharmacokinetics in healthy volunteers.

Authors:  Christina L Aquilante; Lane R Bushman; Shannon D Knutsen; Lauren E Burt; Lucille Capo Rome; Lisa A Kosmiski
Journal:  Hum Genomics       Date:  2008-09       Impact factor: 4.639

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.